Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07291154

Impact of APP-assisted Patient Management on the Quality Control of Blood Purification Therapy

Many maintenance hemodialysis (MHD) patients develop negative outlooks due to their illnesses and complications, making their quality of life and prognosis a clinical concern. Effective life management and treatment cooperation are crucial to improving dialysis quality and patient outcomes. This trial aims to evaluate whether management through the "Yueya" mini-program and WeChat can provide personalized guidance such as health education, diet, exercise, medication supervision, and condition monitoring to enhance treatment compliance, quality of life, strengthen quality control in the hemodialysis unit, and improve patient prognosis.

Patients will be divided into a group receiving support via the "Yueya" mini-program and WeChat, and a control group receiving routine care. Clinical and laboratory indicators, cardiovascular events, death, hospitalization, quality of life, and compliance will be recorded and compared between groups to assess the impact of APP-assisted patient management on the quality of MHD blood purification therapy and the prognosis of MHD patients.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

End Stage Renal Disease (ESRD) Chronic Disease Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Kidney Failure, Chronic Maintenance Hemodialysis Male Urogenital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, 400016, China

Location status: Recruiting

Location contact

Yunfeng Xia Dr

CONTACT

[email protected]

86-23-89012687

About this study

Affected by their own diseases and various complications, many maintenance hemodialysis (MHD) patients have a negative and pessimistic attitude toward life. Their quality of life and prognosis have always been a concern for clinicians. Therefore, how to adjust and manage the lives of these patients, enable them to actively cooperate with various treatment methods, maximize the quality of blood purification therapy, and improve their quality of life and prognosis has become an extremely important research topic.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with stage 5 chronic kidney disease, who have received maintenance hemodialysis for more than 3 months, are aged between 18 and 75 years old, and have regular dialysis three times a week.
  • Patients with relatively stable condition, who are able to take care of themselves and willing to cooperate with the study.
  • Patients who can understand and proficiently use WeChat and the "Yueya" mini - program used in this study.

Exclusion criteria

  • Patients with communication barriers or other conditions that prevent them from cooperating with the study.
  • Patients who have a history of acute myocardial infarction, cerebral infarction or intracerebral hemorrhage in the past six months.
  • Patients who are not willing to actively cooperate with the study.
  • Patients with severe liver cirrhosis, active tuberculosis and AIDS.

Treatment and study plan

APP-based management

Behavioral

Based on patients' specific conditions such as age, gender, primary disease, and complications, the APP-based management will provide individualized and round-the-clock guidance for dialysis patients in their daily lives through the "Yueya" mini-program and WeChat. This guidance covers various aspects, including health knowledge education, diet and exercise guidance, medication supervision, condition monitoring, and real-time feedback.

Primary outcomes

  1. mortality rate

    Time frame: About 1 year

    In this study, mortality rate was used as a prognostic indicator.

  2. Hospitalization rate

    Time frame: About 1 year

    In this study, the hospitalization rate was used as a prognostic indicator.

  3. Kidney Disease Quality of Life

    Time frame: About 1 year

    Measuring the quality of life of hemodialysis patients through the Kidney Disease Quality of Life-36（KDQOL-36） scale. If the KDQOL-36 score increases, the quality of life is considered to be improved.

  4. Incidence of cardiovascular events

    Time frame: About 1 year

Study contacts

Contact information is provided by the study sponsor or research team.

Yunfeng Xia Dr

CONTACT

[email protected]

86-023-89012687

Sponsors and collaborators

Lead sponsor

Yunfeng Xia

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 18, 2025
Registry last updated
Dec 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.